Weight Loss Drug Mounjaro to launch in UK ‘within weeks’

Mounjaro is the new weight loss drug to be approved for use in Britain and it will become available “within weeks”.

Weight Loss Drug Mounjaro to be Available in UK f

"This approval enables access to the approved Mounjaro pen"

Mounjaro is an American weight loss drug and after being approved for use in Britain, it could be available “within weeks”.

It was approved in a four-dose injection pen format.

Also known as tirzepatide, it is a diabetes drug that was authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) to help overweight adults lose and manage weight in November 2023.

The authorisation of the Mounjaro ‘KwikPen’ means the US pharmaceutical company Eli Lilly will be able to “begin supply to the UK within weeks”.

This is according to Laura Steele, the company’s President and General Manager of UK and Northern Europe.

The Mounjaro KwikPen gives four doses for once-a-week treatment over a month and has been approved to treat adults with Type 2 diabetes and for weight management in obese adults.

It can also treat overweight adults who have weight-related health problems like prediabetes, high blood pressure, high cholesterol, or heart problems.

Julian Beach, MHRA interim executive director of healthcare quality and access, said:

“The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people’s health, is clear.

“This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month’s treatment, of one dose per week.”

After Ozempic, Mounjaro was approved for NHS use in September 2023 by the National Institute for Health and Care Excellence (NICE) as an option for patients with type 2 diabetes who do not have the condition under control.

However, NICE is yet to approve the use of the drug for obesity.

The drug’s active component aids in lowering elevated sugar levels in individuals with Type 2 diabetes.

Additionally, it functions as a weight management medication by inducing a sense of fullness in patients and reducing their food cravings.

The recent approval from the MHRA is grounded in the findings of a bridging study, demonstrating that the effectiveness and safety of the multidose Mounjaro KwikPen are anticipated to mirror those of the single-dose pen.

Douglas Twenefour, head of care at Diabetes UK, said:

“We hope the MHRA’s approval of this device will help people living with Type 2 diabetes, who are eligible, to access this effective treatment.

“Supporting people with Type 2 diabetes to lose weight and manage their blood sugar levels is key to reducing the risk of diabetes-related complications, and tirzepatide (Mounjaro) expands the range of treatment options available to help people achieve this.”

However, MHRA warned that Mounjaro might affect how well the contraceptive pill works in obese or overweight female patients.

It also listed potential side effects of the medicine. This includes:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation.

The agency added that low blood sugar is also “very common” in patients with diabetes.

The MHRA said it will keep the safety and effectiveness of Mounjaro under close review.

Dhiren is a News & Content Editor who loves all things football. He also has a passion for gaming and watching films. His motto is to "Live life one day at a time".

  • What's New



  • Polls

    How often do you Exercise?

    View Results

    Loading ... Loading ...
  • Share to...